CAPN3 and neoplasm: The specific and selective KDM1A inhibitor, NCL-1, may provide an avenue to reprogram aggressive neuroblastoma biology to a less proliferative and more differentiated state, and reduce hypoxia-associated pro-angiogenic pathways to disturb tumor vascularization.